Clinical trial NCT05053022: A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
Official title: A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitiligo
Lead sponsor: Crown Laboratories, Inc.
Sponsor class: INDUSTRY
First posted: 2021-09-22
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A proof of concept study to determine the safety and efficacy of Microneedling in patients with stable Vitiligo.
Primary purpose: TREATMENT

Brief summary: This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo. Vitiligo is an autoimmune depigmentation disease of the skin that is characterized by the destruction of epidermal melanocytes by CD8+ T cells. The pathogenesis of Vitiligo has been linked to autoimmunity, oxidative stress, and genetic susceptibility.

Detailed description: Microneedling is a minimally invasive technique developed for skin rejuvenation. In the treatment for vitiligo, the procedure causes micro-inflammations on the epidermis and enhances melanocytes and keratinocytes migration. This process leads to the stimulation and repigmentation of vitiligo areas. Several topical therapies such as Tacrolimus and 5-Fluorouracilused in conjunction with microneedling have yielded favorable repigmentation results. This study aims to evaluate the repigmentation rates of microneedled vitiligo patches without any topical medications other than sunscreen.

There will be a total of 8 -12 treatments over the course of 244 days, with subjects receiving a treatment every 2 weeks.

Eligibility criteria: Inclusion Criteria:

1. Adult male or female, ages 18 through 60.
2. Clinical diagnosis of stable Vitiligo (no changes within the past 6 months) on any of the following body areas: face, neck, trunk, extremities, hands, feet (excluding digits).
3. Subjects in generally good health and free of any conditions which, in the opinion of the investigator, would interfere with the study assessments.
4. Subjects willing to discontinue all current therapies for vitiligo for the duration of the study.
5. Women of childbearing potential agree to take a urine pregnancy test at the Baseline visit and Final visit.
6. Individuals that are willing to provide written informed consent and are able to read, speak, write and understand the informed consent document.
7. Willingness to cooperate and participate by following study requirements for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately.

Exclusion Criteria:

1. Individuals diagnosed with known allergies to facial or general skin care products.
2. Individuals who have presence of an active systemic or local skin disease, apart from vitiligo, that may affect wound healing. Uncontrolled disease such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
3. Individuals with sensitivity to topical lidocaine, stainless steel, nickel, or chromium
4. Individuals who have a recent or current history of inflammatory skin disease or cancerous/pre-cancerous lesion.
5. Subjects currently or within the past 3 months on Vitiligo topical or systemic treatments.
6. Use of skin lighteners or bleaching agents; hydroquinone, phenol peels or harsh chemicals.
7. Individuals who have the inability to understand instructions or to give informed consent.
8. Individuals who have a history of chronic drug or alcohol abuse.
9. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
10. Individuals who are current smokers.
11. Individuals who are nursing, pregnant, or planning to become pregnant during the study according to subject self-report.
12. Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
13. Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study.
14. Individuals who are currently participating in any other study involving the use of investigational device or drugs at another research facility or doctor's office within 4 weeks prior to inclusion into the study.
15. Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments)

Primary outcomes:
measure: Physician's Global Assessment (PGA)
timeFrame: Through Study Completion, over the course of 244 days
Secondary outcomes:
measure: Subject's assessment of their pre and post-treatment images using the Vitiligo Noticeability Scale (VNS)
timeFrame: Through Study Completion, over the course of 244 days
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Crown Laboratories
state: Texas
Study officials:
References: